Interferon Biology and LAG-3 Shedding in PD-(L)1 plus LAG-3 Immunotherapy

被引：3

作者：

Karapetyan, Lilit ^{[1
,2
]}

Luke, Jason J. ^{[3
,4
,5
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[2] Univ S Florida, Dept Oncol Sci, Tampa, FL USA

[3] UPMC Hillman Canc Ctr, Pittsburgh, PA USA

[4] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA

[5] 5150 Ctr Ave,Room 1 27C, Pittsburgh, PA 15232 USA

来源：

CLINICAL CANCER RESEARCH | 2023年 / 29卷 / 05期

关键词：

CELL; RELATLIMAB; NIVOLUMAB;

D O I：

10.1158/1078-0432.CCR-22-3312

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Targeting coinhibitory receptors on dysfunctional T cells may improve response to anti-PD-(L)1 in the IFNy associated T-cell-inflamed tumor microenvironment. The bispecific lymphocyte activation gene 3 (LAG-3) and PD-L1 blocking antibody FS118, potentially through LAG-3 shedding, represents a promising strategy to improve immune checkpoint blockade. Soluble LAG-3 is an intriguing biomarker for LAG-3 drug activity.

引用

页码：835 / 837

页数：3

共 50 条

[1] Simultaneous inhibition of PD-1 and LAG-3: the future of immunotherapy?
Abi-Aad, Sasha-Jane
Zouein, Joseph
Chartouni, Antoine
Naim, Nabih
Kourie, Hampig Raphael
IMMUNOTHERAPY, 2023, 15 (08) : 611 - 618
[2] LAG-3 and PD-1 blockade raises the bar for melanoma
Robert, Caroline
NATURE CANCER, 2021, 2 (12) : 1251 - 1253
[3] Noninvasive Immunotyping and Immunotherapy Monitoring of Lung Cancers via Nuclear Imaging of LAG-3 and PD-L1
Zhao, Lishu
Ge, Jianxian
Zhang, Ruru
Wang, Hao
Liu, Xinyue
Xu, Kandi
Liu, Yujin
Zhao, Wencheng
Zhang, Wengang
Ye, Li
Chen, Zhimin
Zeng, Jianfeng
He, Yayi
Gao, Mingyuan
ADVANCED SCIENCE, 2024,
[4] Pseudoprogression in a patient with metastatic melanoma treated with PD-1 and LAG-3 inhibition
Wu, Lawrence W.
Tao, Jacqueline J.
McDonnell, Diana
Izar, Benjamin
MELANOMA RESEARCH, 2024, 34 (04) : 382 - 385
[5] LAG-3 as a therapeutic target in melanoma
Terlecka, Anna M.
Rutkowski, Piotr
Sobczuk, Pawel
ONCOLOGY IN CLINICAL PRACTICE, 2024,
[6] The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition
Kreidieh, Firas Y.
Tawbi, Hussein A.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
[7] The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition
Kreidieh, Firas Y.
Tawbi, Hussein A.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
[8] Development of a LAG-3 immunohistochemistry assay for melanoma
Johnson, Lori
McCune, Bryan
Locke, Darren
Hedvat, Cyrus
Wojcik, John B.
Schroyer, Caitlin
Yan, Jim
Johnson, Krystal
Sanders-Cliette, Angela
Samala, Sujana
Dillon, Lloye M.
Anderson, Steven
Shuster, Jeffrey
JOURNAL OF CLINICAL PATHOLOGY, 2023, 76 (09) : 591 - 598
[9] Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3+anti-PD-1-based immunotherapies
Gide, Tuba N.
Paver, Elizabeth C.
Yaseen, Zarwa
Maher, Nigel
Adegoke, Nurudeen
Menzies, Alexander M.
da Silva, Ines Pires
Wilmott, James S.
Long, Georgina V.
Scolyer, Richard A.
ONCOIMMUNOLOGY, 2023, 12 (01):
[10] Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma
Harris-Bookman, Sarah
Mathios, Dimitrios
Martin, Allison M.
Xia, Yuanxuan
Kim, Eileen
Xu, Haiying
Belcaid, Zineb
Polanczyk, Magdalena
Barberi, Theresa
Theodros, Debebe
Kim, Jennifer
Taube, Janis M.
Burger, Peter C.
Selby, Mark
Taitt, Corina
Korman, Alan
Ye, Xiaobu
Drake, Charles G.
Brem, Henry
Pardoll, Drew M.
Lim, Michael
INTERNATIONAL JOURNAL OF CANCER, 2018, 143 (12) : 3201 - 3208

← 1 2 3 4 5 →